Palobiofarma plans to start to key multicenter Phase II clinical studies the second quarter of 2018. The studies will evaluate the preliminary efficacy of PBF-677 in Ulcerative Colitis patients and the efficacy of PBF-680 is mild to moderate asthmatics.
Recent News
- Palobiofarma announces significant advances in the clinical development of PBF-999 for Prader-Willi Syndrome
- Palobiofarma announce several important milestones dealing with the clinical development of PBF-999 for Prader-Willi Syndrome
- Palobiofarma Announces Completion of Dual A2A/H3 Receptor Antagonist Research Project for Parkinson’s Disease
- Palobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, Spain
- PAMPLONA, SPAIN, SEPTEMBER 9th, 2024—Palobiofarma is pleased to announce today positive top-line results in a Phase 2 trial of the novel oral drug PBF-680 in patients with moderate-to-severe COPD.